Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.
NVO Key Statistics
NVO News
Key Points Novo Nordisk's Wegovy pill has created another boom in the GLP-1 drug market. Eli Lilly recently introduced its Foundayo pill for weight loss, three...
Key Points Agios shares rose after strong earnings and Aqvesme's commercial launch. Mitapivat faces competition from Novo Nordisk's etavopivat in the treatmen...
The US FDA has proposed removing semaglutide, tirzepatide, and liraglutide from federal compounding exemptions. The proposal would limit pharmacies from compou...
Analyst ratings
62%
of 34 ratingsMore NVO News
Shares in weight-loss drug maker Novo Nordisk (NVO) climbed today after a study showed a link between the treatment and people battling alcoholism. Claim 55% Of...
A GLP-1 medication helped people with obesity who were undergoing treatment for alcohol-use disorder drink less, according to new research. The study, which wa...
GoodRx (GDRX) announced that it is providing access to self-pay pricing for Novo Nordisk’s (NVO) Ozempic pill, helping eligible patients with type 2 diabetes ob...
If you are wondering whether Novo Nordisk's current share price reflects its true worth, the recent numbers give you plenty to think about. The stock last clos...
Shares in drugmakers Eli Lilly (LLY) and Novo Nordisk (NVO) climbed on Thursday morning after the U.S. health watchdog proposed not to allow outsourcing facilit...
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. The Food and Drug Administration on Thursday proposed ex...
More than 20,000 people have started taking Eli Lilly 's GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday....
